# US 2022/0016139 A1 · Methods of inhibiting hiv infections by pre-exposure prophylaxis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016139 A1
- Document ID: US20220016139A1
- Status: Published application
- Kind: A1
- Application number: 17/186,534
- Filed: 2021-02-26
- Published: 2022-01-20
- Earliest claimed: 2006-02-03
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human
- Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
- Inventors: Walid Heneine; Thomas M. Folks; Robert Janssen; Ronald A. Otten; Jose Gerardo Garcia Lerma
- Web page: https://patentgrep.com/patent/US20220016139A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/18: for HIV
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

## Claims

### Claim 1

A method, comprising:
prohibiting a primate subject from acquiring an immunodeficiency retrovirus infection by:
a. determining if the primate subject is negative for a detectable immunodeficiency retrovirus infection; and
b. orally administering a plurality of doses of at least one tablet comprising 200 mg emtricitabine (FTC) and a pharmaceutically effective amount of a tenofovir prodrug to the subject if the primate subject is negative for the immunodeficiency retrovirus infection, wherein at least a first dose occurs before the primate subject is potentially exposed to the immunodeficiency retrovirus; and
testing the primate subject after the oral administration to confirm that the subject has remained negative for the detectable immunodeficiency retrovirus infection following a plurality of doses.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tenofovir prodrug is tenofovir disoproxil fumarate in an amount of 300 mg.

### Claim 3 (depends on 1)

The method of claim 1, wherein orally administering the at least one tablet comprises orally administering one tablet per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tenofovir prodrug comprises a tenofovir ester.

### Claim 5 (depends on 1)

The method of claim 1, wherein the oral administration of the at least one tablet results in an area under the plasma concentration-time curve (AUC) over a 24 hour interval for emtricitabine in the primate subject of 6.88 μg·hr/mL to 13.12 μg·hr/mL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the oral administration of the at least one tablet results in an area under the plasma concentration-time curve (AUC) over a 24 hour interval for emtricitabine in the primate subject of 11 μg·hr/mL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the testing the primate subject comprises a polymerase chain reaction (PCR) assay to detect the presence of the immunodeficiency retroviral genome in the primate subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the oral administration of the at least one tablet results in an absence of an immunodeficiency retrovirus seroconversion in the primate subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the primate subject is an adult human subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein the oral administration of the plurality of doses of the at least one tablet comprises a treatment regimen over a time period, and wherein the testing of the primate subject occurs regularly during the time period of the treatment regimen.

### Claim 11 (depends on 1)

The method of claim 1, wherein the oral administration of the plurality of doses of the at least one tablet prohibits a subsequent HIV-1 exposure of the primate subject from becoming a self-replicating HIV-1 infection.

### Claim 12

A method, comprising
inhibiting a human subject who is uninfected with human immunodeficiency virus 1 (HIV-1) from becoming infected, by:
a. screening the human subject to confirm that the subject does not have a detectable HIV-1 infection;
b. orally administering a plurality of doses of at least one tablet comprising 200 mg emtricitabine (FTC) and a pharmaceutically effective amount of a prodrug of tenofovir to the subject if the primate subject is confirmed to not have an HIV-1 infection, wherein the administration occurs before the human subject is exposed to HIV-1; and
c. testing the human after the subject has been potentially exposed to HIV-1 to confirm that the human subject does not have an HIV-1 infection.

### Claim 13 (depends on 12)

The method of claim 12, wherein the prodrug of tenofovir is tenofovir disoproxil fumarate in an amount of 300 mg.

### Claim 14 (depends on 12)

The method of claim 12, wherein the prodrug of tenofovir is a tenofovir ester.

### Claim 15 (depends on 12)

The method of claim 12, wherein administration of a single dose of the tablet results in an area under the plasma concentration-time curve (AUC) for emtricitabine of about 6.88 μg·hr/mL to about 13.12 μg·hr/mL.

### Claim 16 (depends on 12)

The method of claim 12, wherein administration of a single dose of the tablet results in an area under the plasma concentration-time curve (AUC) for emtricitabine of 11 μg·hr/mL.

### Claim 17 (depends on 12)

The method of claim 12, wherein the oral administration is a daily oral dose of the tablet.

### Claim 18 (depends on 17)

The method of claim 17, wherein the daily oral dose of the tablet inhibits a subsequent HIV-1 exposure of the human subject from becoming a self-replicating HIV-1 infection.

### Claim 19 (depends on 17)

The method of claim 17, wherein the daily oral dose of the tablet is administered daily for several months, and wherein the subject is tested for HIV-1 infection during the course of the several months of administration.

### Claim 20 (depends on 19)

The method of claim 19, wherein the daily oral dose of the tablet results in steady-state plasma levels of emtricitabine and tenofovir in the primate subject.

### Claim 21

A pre-exposure prophylactic treatment method for preventing an exposure of a human subject to human immunodeficiency virus 1 (HIV-1) from becoming a HIV-1 self-replicating infection, comprising:
a. confirming that the human subject is serologically negative for HIV-1;
b. orally administering a plurality of daily doses of a tablet comprising 200 mg emtricitabine (FTC) and a pharmaceutically effective amount of a tenofovir prodrug to the human subject if the human subject is serologically negative for HIV-1, wherein the administration is initiated before the human subject has been exposed to HIV-1; and
c. testing the human subject after several months of the oral administration to confirm that the subject does not have a self-replicating HIV-1 infection.

### Claim 22 (depends on 21)

The treatment method of claim 21, wherein the tenofovir prodrug is tenofovir disoproxil fumarate in an amount of 300 mg.

### Claim 23 (depends on 21)

The treatment method of claim 21, wherein the tenofovir prodrug is a tenofovir ester.

### Claim 24 (depends on 23)

The treatment method of claim 23, wherein if the testing determines that the subject does not have a self-replicating HIV-1 infection after the several months of daily doses of the tablet, then continuing with the daily doses of the tablet.

### Claim 25 (depends on 23)

The method of claim 23, wherein the oral administration of the daily doses of the tablet results in the human subject being protected from developing a self-replicating HIV-1 infection following sexual exposure to an HIV-1-infected subject.

### Claim 26

A pre-exposure prophylactic treatment method for preventing an exposure of a human subject to human immunodeficiency virus 1 (HIV-1) from becoming a HIV-1 self-replicating infection, comprising:
a. confirming that the human subject is negative for an HIV-1 infection;
b. orally administering a daily dose of a tablet comprising 200 mg emtricitabine (FTC) and a tenofovir prodrug to the human subject for several months if the human subject is serologically negative for HIV-1; and
c. testing the human subject after the several months of the oral administration to confirm that the human subject has not developed a self-replicating retroviral infection.

### Claim 27 (depends on 26)

The method of claim 26, wherein the tenofovir prodrug is tenofovir disoproxil fumarate in an amount of 300 mg.

### Claim 28 (depends on 26)

The method of claim 26, wherein the tenofovir prodrug is a tenofovir ester.

### Claim 29 (depends on 26)

The method of claim 26, wherein the oral administration of the tablet results in an area under the plasma concentration-time curve (AUC) over a 24 hour interval for emtricitabine in the human subject of 10.0±3.12 μg·hr/mL.

### Claim 30 (depends on 26)

The method of claim 26, wherein the oral administration of the tablet results in an area under the plasma concentration-time curve (AUC) over a 24 hour interval for emtricitabine in the human subject of 11 μg·hr/mL.

### Claim 31 (depends on 1)

A kit, comprising a plurality of doses of a tablet comprising 200 mg emtricitabine (FTC) and a pharmaceutically effective amount of a tenofovir prodrug, for use in the method of claim 1.
